附件一、技術推廣

組蛋白去乙醯酶抑制劑做為新型抗神經病變疾病用藥設計與合成

（以下內容一頁為限，不可揭露關鍵技術內容；填表完成後請刪除此行）

發明人：陳基旺 教授
單　位：國立臺灣大學　藥學系/研究所
簡　歷：(可列出相關連結，例如系所、研究室網頁)
藥學系 名譽教授
http://rx.mc.ntu.edu.tw/myDOP/SCENE/FACULTY/facultyview.php?malangue=&rub=faculty//1//c4ca4238a0b923820dcc509a6f75849b229181faWepZXh06QQU
http://rx.mc.ntu.edu.tw/myDOP/SCENE/FACULTY/mainfaculty.php?rub=faculty//5

市場及需求:
目前神經退化性疾病，例如阿滋海默症，漸凍人等疾病，仍無有效的治療藥物，因此是當前有龐大市場的醫療未滿需求(Unmet Medical Need)。

技術摘要:
選擇性組蛋白去乙醯酶抑制劑，具有促進神經修復效果。由於目前市場上具有同樣效果的競爭分子有限，因此開發新型的選擇性組蛋白去抑制劑可提供病人更多的藥物選擇。

優勢:
研發產品具有全新的藥物結構且對組蛋白去乙醯酶有良好的抑制活性。由於為全新類型之結構，相信經由構效關係優化後必能找到具有良好成藥性之產品。

競爭產品:
無

專利簡述:
本研究團隊具有十多年研究經驗，目前已掌握系列化合物構效關係，相信技轉後能於短時間進入臨床開發。由於新藥研發時程較長，預計產品進入臨床開發後再發表專利則可取得較長的產品專利保護優勢。

聯絡方式: 臺大產學合作總中心

Tel: 02-3366-9945,　E-mail: ntuciac@ntu.edu.tw

Title of Invention

(Below is limited to 1-page only; be careful not to disclose vital technology content. Please delete these words when the document is finished)

PI： Professor Ji-Wang Chern
Department of Pharmacy, National Taiwan Univ.

Experience:

Emeritus Professor

http://rx.mc.ntu.edu.tw/myDOP/SCENE/FACULTY/facultyview.php?malangue=EN&rub=faculty//1//c4ca4238a0b923820dcc509a6f75849b220857faWepZXh06QQU

Market Needs:

Up to date, there is no effective drug for the treatment of neuron degenerative diseasese such as Alzheimer's disease and Amyotrophic lateral sclerosis (ALS). Thus developing new and safe agents to address this high potential market value disease is unmet medical need.

Our Technology:

Selective HDAC inhibitor is proved to be effective in neuron reparing. Since there is very few competitor molecule with similar bioactivity, thus developing new type of HDAC inhibitor could provide choice for the patient.

Strength:

Novel chemical entity as HDAC inhibitors with well-defined SAR correlation could provide high success rate to develop a potential drug-like agent/product.

Competing Products:

None

Intellectual Properties:

The development team have drug discovery-development experience of 10+ years. Since the SAR correlation of target have been well studied, the preclinical development is believed to be fast for IND submission. Since the time for drug development is long, patent filing in development stage will provide sufficient protection in patent lifecycle management.

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU
Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw